RxDoctor Payments Data

Javaria Asif, MD

Family Medicine · Seminole, OKNPI 1538355441

Payments from drug & device makers

$8,486in general payments, 2019–2025

Across 519 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$943
  • AbbVie$916
  • Boehringer Ingelheim$667
  • AstraZeneca$552
  • Amgen$522
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$8,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,486 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$109,782
Medicare patients
283
Services billed
1,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$163,421
JardianceEmpagliflozin106$122,255
EliquisApixaban39$57,048
TrulicityDulaglutide35$45,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$45,024
MounjaroTirzepatide27$38,044
LinzessLinaclotide26$27,037
XareltoRivaroxaban13$21,954
MyrbetriqMirabegron19$17,909
Synjardy XrEmpagliflozin/Metformin Hcl12$15,885
JanuviaSitagliptin Phosphate11$14,237
FarxigaDapagliflozin Propanediol12$14,025
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,717
SynthroidLevothyroxine Sodium83$6,731
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,314$163,421118 claims
Boehringer IngelheimJardiance, Synjardy Xr$667$138,140118 claims
Lilly USA, LLCTrulicity, Mounjaro$943$83,31262 claims
PfizerEliquis$182$57,04839 claims
GSKTrelegy Ellipta$448$45,02455 claims
AbbVieLinzess, Synthroid$916$33,767109 claims
AstraZenecaFarxiga, Breztri Aerosphere$552$24,74225 claims
Astellas Pharma US IncMyrbetriq$87$17,90919 claims
MerckJanuvia$101$14,23711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Seminole

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →